Table 4.
T cell immune response of BALB- neu T mice following vaccination with rV- neu T
|
T cell
in vitro
stimulus |
Neu peptide sequence |
IL-2 release* |
IFN-γ |
||
|---|---|---|---|---|---|
| rV- neu T | V-wt | rV- neu T | V-wt | ||
|
r15.3 |
TYVPANASL |
208 |
44 |
519 |
≤18 |
|
r41 |
DMVLWKDVFRKNNQL |
359 |
43 |
475 |
≤18 |
|
r98 |
IAPLRPEQLQVFETL |
343 |
44 |
510 |
≤18 |
|
r141 |
LPCHPECQPQNSSET |
209 |
43 |
555 |
≤18 |
|
r156 |
GICQPCPINCTHSCV |
265 |
45 |
365 |
≤18 |
|
r166 |
VLLFLILVVVVGILI |
239 |
42 |
585 |
≤18 |
|
GAG |
|
35 |
41 |
3 |
≤18 |
| ConA | 1450 | 2800 | 2890 | 3150 | |
*Spleen cells from vaccinated mice were stimulated in vitro with Neu-specific peptides. IL-2 and IFN-γ was quantitated in the supernatant (pg/ml) as a measure of T cell immunoreactivity with specific Neu epitopes. ConcanavalinA (ConA) for global T cell activation and an unrelated gag peptide served as positive and negative control, respectively.